2026-11-20
Key findings included:
- Durable metabolic improvement: In DIO mice, metabolic homeostasis was maintained for over 14 months after initial weight loss.
- Improved metabolic outcomes: In BDNF+/- mice, treatment stabilized body weight and normalized glucose tolerance (p < 0.05).
- Favorable safety and behavioral outcomes: No uncontrolled cachexia was observed, while aggressive and repetitive chasing behaviors decreased without impairing naturalistic pro-social interactions.
These findings highlight the potential of targeted AAV gene delivery to address both metabolic dysfunction and associated neurobehavioral manifestations in rare genetic forms of obesity.
For therapies targeting specific brain regions such as the VmH, precise vector delivery, appropriate transgene expression, and consistent vector potency are particularly important. Capsid and construct optimization, together with reliable vector characterization and scalable manufacturing, can help support the transition from promising preclinical findings to clinical development.
As part of the broader gene therapy ecosystem, Genevoyager provides end-to-end CRO/CDMO services, from drug discovery to large-scale manufacturing, leveraging both HEK293 and our proprietary Bac/Sf9 AAV production platforms. Our proprietary Bac/Sf9 system enables high-quality AAV production with minimal impurities and no detectable replication-competent AAV (rcAAV). With 30+ drug development projects and multiple IIT/IND submissions supported, Genevoyager has helped advance AAV-based gene therapies and recombinant protein vaccines into clinical development, including programs targeting Parkinson’s disease, refractory epilepsy, hepatitis B, and cancer, with selected programs receiving FDA IND clearance and reaching Phase I clinical trials. Backed by extensive experience, we are committed to delivering safe, high-quality solutions to academic, pharmaceutical, and biotech partners worldwide.
Source:
https://meiragtx.gcs-web.com/news-releases/news-release-details/meiragtx-announces-oral-presentation-obesityweek-2026
Image source:
https://www.nature.com/articles/nrg2594
Note: The studies discussed above were conducted independently and are not affiliated with Genevoyager. We’re sharing them here to promote discussion and exchange within the community.
Genevoyager Inc
3675 Market Street, Suite 200, Philadelphia, PA 19104
Tel: +1 (215) 205-6963
E-mail: hui.wang@genevoyager.com | globalbd@genevoyager.com
BrainVTA LLC
100 E Lancaster Ave, Suite LIMR R241, Wynnewood, PA 19096
Genevoyager (Wuhan) Co., Ltd.
No. 128, Guanggu 7th Rd, East Lake High-tech Development Zone, Wuhan, China
Tel: +86 17720522078 | +86 027-65023363
E-mail: marketing@genevoyager.com
Genevoyager Inc
3675 Market Street, Suite 200, Philadelphia, PA 19104
Tel: +1 (215) 205-6963
E-mail: hui.wang@genevoyager.com | globalbd@genevoyager.com
BrainVTA LLC
100 E Lancaster Ave, Suite LIMR R241, Wynnewood, PA 19096
Genevoyager (Wuhan) Co., Ltd.
No. 128, Guanggu 7th Rd, East Lake High-tech Development Zone, Wuhan, China
Tel: +86 17720522078 | +86 027-65023363
E-mail: marketing@genevoyager.com